Contract drug research and manufacturing firm Syngene International Ltd has lowered its full-year revenue guidance from mid-single digit growth to negative 2-3%, as destocking of a single biologics ...
Monoclonal antibodies (mAbs) have revolutionized modern medicine, offering precision therapies for cancer, autoimmune disorders, infectious diseases, and numerous other advantages. The global mAb ...
Syngene International Ltd. is the country's largest integrated CRAMS/CRDMO, offering services to various sectors including pharmaceuticals, biotechnology, and consumer goods. Syngene International ...
Syngene International adapts to industry challenges, focusing on balanced growth in R&D and manufacturing. Biologics are a key growth driver for Syngene, with expanded capabilities for discovery and ...
Johnson & Johnson expands its Tar Heel State presence with $2 billion investment, and Syngene sites first U.S. facility in Baltimore. Johnson & Johnson is expanding its footprint in North Carolina ...
Shares of Syngene International Ltd tumbled 10 per cent in Thursday's trade after the company gave a muted revenue guidance for FY26. Post Q4 results, Managing Director and CEO at Syngene ...
Syngene International Ltd, a wholly owned subsidiary of Biocon Ltd, and Baxter International, a global pharmaceutical company, have collaborated to establish the Baxter Global Research Center at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results